$VRDN
Viridian Therapeutics, Inc.\DE

2020 Form 10-K Financial Statement

#000159075021000029 Filed on March 26, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $1.050M $880.0K $4.461M
YoY Change -76.46% 84.87% -46.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.27M $2.530M $11.35M
YoY Change 16.92% -6.3% 2.71%
% of Gross Profit
Research & Development $28.30M $8.417M $34.79M
YoY Change -18.65% 2.22% 14.37%
% of Gross Profit
Depreciation & Amortization $200.0K $70.00K $300.0K
YoY Change -33.33% 0.0% 0.0%
% of Gross Profit
Operating Expenses $111.4M $8.417M $46.44M
YoY Change 139.94% 2.22% 11.98%
Operating Profit -$110.4M -$41.98M
YoY Change 162.94% 26.89%
Interest Expense -$340.0K -$50.00K $110.0K
YoY Change -409.09% -135.71% -71.05%
% of Operating Profit
Other Income/Expense, Net $173.0K -$47.00K $941.0K
YoY Change -81.62% -134.56% -24.96%
Pretax Income -$110.7M -$10.12M -$41.87M
YoY Change 164.44% -1.94% 28.04%
Income Tax
% Of Pretax Income
Net Earnings -$110.7M -$10.12M -$41.87M
YoY Change 164.41% -1.93% 28.04%
Net Earnings / Revenue -10544.29% -1149.77% -938.65%
Basic Earnings Per Share -$31.13
Diluted Earnings Per Share -$31.13 -$4.685M -$20.03M
COMMON SHARES
Basic Shares Outstanding 3.557M shares 31.79M shares
Diluted Shares Outstanding 3.557M shares

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.6M $26.80M $26.80M
YoY Change 376.12% -57.12% -57.12%
Cash & Equivalents $45.90M $24.85M $24.80M
Short-Term Investments $81.70M $2.000M $2.000M
Other Short-Term Assets $2.000M $2.800M $2.800M
YoY Change -28.57% -3.45% -3.45%
Inventory
Prepaid Expenses
Receivables $108.0K $100.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $129.6M $29.74M $29.70M
YoY Change 336.36% -54.51% -54.59%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $523.0K $500.0K
YoY Change 60.0% -28.06% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $1.700M $523.0K $600.0K
YoY Change 183.33% -32.69% -14.29%
TOTAL ASSETS
Total Short-Term Assets $129.6M $29.74M $29.70M
Total Long-Term Assets $1.700M $523.0K $600.0K
Total Assets $131.3M $30.26M $30.30M
YoY Change 333.33% -54.25% -54.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $1.096M $1.100M
YoY Change -36.36% 91.94% 83.33%
Accrued Expenses $9.700M $5.108M $5.100M
YoY Change 90.2% 32.06% 30.77%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.000M $4.000M
YoY Change -100.0% 73.91% 73.91%
Total Short-Term Liabilities $10.70M $10.18M $10.20M
YoY Change 4.9% 51.2% 52.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.300M $4.300M
YoY Change -100.0% -46.25% -46.25%
Other Long-Term Liabilities $500.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $500.0K $0.00 $4.300M
YoY Change -88.37% -100.0% -46.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.70M $10.18M $10.20M
Total Long-Term Liabilities $500.0K $0.00 $4.300M
Total Liabilities $11.20M $14.51M $14.50M
YoY Change -22.76% -1.99% -2.03%
SHAREHOLDERS EQUITY
Retained Earnings -$168.2M
YoY Change 33.15%
Common Stock $23.00K
YoY Change -92.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.0M $15.75M $15.80M
YoY Change
Total Liabilities & Shareholders Equity $131.3M $30.26M $30.30M
YoY Change 333.33% -54.25% -54.16%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$110.7M -$10.12M -$41.87M
YoY Change 164.41% -1.93% 28.04%
Depreciation, Depletion And Amortization $200.0K $70.00K $300.0K
YoY Change -33.33% 0.0% 0.0%
Cash From Operating Activities -$29.78M -$7.810M -$36.06M
YoY Change -17.41% -4.41% 34.32%
INVESTING ACTIVITIES
Capital Expenditures $42.00K $0.00 $84.00K
YoY Change -50.0% -100.0% -81.12%
Acquisitions
YoY Change
Other Investing Activities $3.000K $7.000M $0.00
YoY Change -23.41% -100.0%
Cash From Investing Activities -$50.48M $7.000M $28.23M
YoY Change -278.85% -22.99% -194.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $2.283M
YoY Change -100.0% -94.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $101.3M 800.0K $70.00K
YoY Change 144630.0% -8100.0% -99.83%
NET CHANGE
Cash From Operating Activities -$29.78M -7.810M -$36.06M
Cash From Investing Activities -$50.48M 7.000M $28.23M
Cash From Financing Activities $101.3M 800.0K $70.00K
Net Change In Cash $21.05M -10.00K -$7.760M
YoY Change -371.28% -101.1% -47.69%
FREE CASH FLOW
Cash From Operating Activities -$29.78M -$7.810M -$36.06M
Capital Expenditures $42.00K $0.00 $84.00K
Free Cash Flow -$29.82M -$7.810M -$36.14M
YoY Change -17.48% -3.7% 32.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7230651 shares
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
6200 Lookout Road
CY2020Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-36483
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001590750
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Registrant Name
EntityRegistrantName
Viridian Therapeutics, Inc./DE
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1187261
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
CY2020 dei City Area Code
CityAreaCode
(720)
CY2020 dei Local Phone Number
LocalPhoneNumber
643-5200
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
CY2020 dei Trading Symbol
TradingSymbol
VRDN
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
58500000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45897000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
81742000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
1999000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1972000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2894000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
129611000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
29739000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
309000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
478000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
857000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q4 us-gaap Assets
Assets
131255000 USD
CY2019Q4 us-gaap Assets
Assets
30262000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
670000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3976000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
301000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1096000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5108000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10674000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10180000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4328000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
544000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2020Q4 us-gaap Liabilities
Liabilities
11218000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
14508000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4231135 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4231135 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2324126 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2324126 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
42000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
23000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
218089000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183900000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278887000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168169000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
120037000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131255000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30262000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1050000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4461000 USD
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
28304000 USD
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
34794000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13265000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11646000 USD
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
69861000 USD
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
111430000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
46440000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-110380000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-41979000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
173000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
941000 USD
CY2020 us-gaap Interest And Debt Expense
InterestAndDebtExpense
508000 USD
CY2019 us-gaap Interest And Debt Expense
InterestAndDebtExpense
835000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-110715000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41873000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-8000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110723000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41870000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110715000 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41873000 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-31.13
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-20.04
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3557065 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2089094 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
51344000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
87000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3970000 USD
CY2019 mgen Warrants Reclassification Of Warrant Liability From Equity
WarrantsReclassificationOfWarrantLiabilityFromEquity
18000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41873000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
95361000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
47000 USD
CY2020 mgen Stock Issued During Period Value Common Stock To Settle Accrued Liabilities
StockIssuedDuringPeriodValueCommonStockToSettleAccruedLiabilities
6000000 USD
CY2020 mgen Stock Issued During Period Value Warrants Exercised Value
StockIssuedDuringPeriodValueWarrantsExercisedValue
550000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
29000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
26000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3645000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-8000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-110715000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
120037000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-110715000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41873000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
84000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
258000 USD
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
65990000 USD
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
6000000 USD
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3645000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3970000 USD
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
281000 USD
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2020 us-gaap Accretion Expense
AccretionExpense
263000 USD
CY2019 us-gaap Accretion Expense
AccretionExpense
340000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
239000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
288000 USD
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-56000 USD
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
432000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-35000 USD
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-99000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-126000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-426000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
525000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5012000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1084000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29779000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36056000 USD
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
81807000 USD
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32690000 USD
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
29371000 USD
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2000000 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
61000000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000 USD
CY2020 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3000 USD
CY2019 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 USD
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10293000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50481000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28226000 USD
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
90997000 USD
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
25104000 USD
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2480000 USD
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2333000 USD
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1726000 USD
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2020 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-44000 USD
CY2019 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101311000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21051000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7760000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32606000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45897000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
267000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
511000 USD
CY2020 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
32000 USD
CY2019 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
3000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278900000 USD
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
127600000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
CY2020 mgen Restructuring And Related Cost Number Of Plan Phases
RestructuringAndRelatedCostNumberOfPlanPhases
2 plan_phase
CY2019 mgen Restructuring And Related Cost Number Of Plan Phases
RestructuringAndRelatedCostNumberOfPlanPhases
2 plan_phase
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div>
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
3000 USD
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-8000 USD
CY2020 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0 USD
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000 USD
CY2019Q3 mgen Restructuring And Related Cost Number Of Plan Phases
RestructuringAndRelatedCostNumberOfPlanPhases
2 plan_phase
CY2020 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2020Q4 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
2400000 USD
CY2020Q4 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
0 USD
CY2020 us-gaap Restructuring Charges
RestructuringCharges
300000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 mgen Classof Warrantor Right Expired In Period Weighted Average Grant Date Fair Value
ClassofWarrantorRightExpiredInPeriodWeightedAverageGrantDateFairValue
787.50
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
498500 shares
CY2019 us-gaap Restructuring Charges
RestructuringCharges
2000000.0 USD
CY2019Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
300000 USD
CY2020Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
0 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3752000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3871000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3443000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3348000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
309000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2020Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
5400000 USD
CY2019Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
2259000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1963000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
508000 USD
CY2020Q4 mgen Accrued License Agreement Liability
AccruedLicenseAgreementLiability
86000 USD
CY2019Q4 mgen Accrued License Agreement Liability
AccruedLicenseAgreementLiability
0 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
796000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
455000 USD
CY2020Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
380000 USD
CY2019Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
284000 USD
CY2020Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2019Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 USD
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
1515000 USD
CY2020Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
0 USD
CY2019Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
66000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
523000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5108000 USD
CY2020 mgen Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
2 renewal_term
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000 USD
CY2020Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.06
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000 USD
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.06
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P26M
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
500000 USD
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
300000 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
300000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
16.00
CY2020 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2019 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2019Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
170502 shares
CY2020Q4 mgen Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
498500 shares
CY2019Q4 mgen Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
3101 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3101 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
268.95
CY2020 mgen Classof Warrantor Right Grantsin Period
ClassofWarrantorRightGrantsinPeriod
500000 shares
CY2020 mgen Classof Warrantor Right Exercise Priceof Warrantsor Rights Exercised During Period
ClassofWarrantorRightExercisePriceofWarrantsorRightsExercisedDuringPeriod
16.50
CY2020 mgen Class Of Warrant Or Right Acquired In Merger In Period
ClassOfWarrantOrRightAcquiredInMergerInPeriod
29446 shares
CY2020 mgen Class Of Warrant Or Right Acquired In Merger In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightAcquiredInMergerInPeriodWeightedAverageGrantDateFairValue
0.15
CY2020 mgen Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
33333 shares
CY2020 mgen Class Of Warrant Or Right Exercised In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue
16.50
CY2020 mgen Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
714 shares
CY2019 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
16.00
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1033256 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4571288 shares
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3645000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3970000 USD
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9600000 USD
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y5M1D
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28099000 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
236000 shares
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-17200000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.004
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.101
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.158
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.313
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.129
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.039
CY2020 mgen Effective Income Tax Rate Reconciliation Section382 Limit Percent
EffectiveIncomeTaxRateReconciliationSection382LimitPercent
-0.249
CY2019 mgen Effective Income Tax Rate Reconciliation Section382 Limit Percent
EffectiveIncomeTaxRateReconciliationSection382LimitPercent
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.004
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22622000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32792000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
494000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10812000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2037000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
829000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1571000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1202000 USD
CY2020Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
2467000 USD
CY2019Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
605000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29191000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46240000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29073000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46240000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
118000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020Q4 mgen Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
118000 USD
CY2019Q4 mgen Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
0 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
118000 USD
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
104100000 USD
CY2020 mgen Tax Credit Carryforward Limitations On Use Amount
TaxCreditCarryforwardLimitationsOnUseAmount
59000000.0 USD
CY2020 mgen Tax Credit Carryforward Limitations On Use Amount
TaxCreditCarryforwardLimitationsOnUseAmount
59000000.0 USD
CY2020 mgen Tax Credit Carryforward Write Off
TaxCreditCarryforwardWriteOff
15300000 USD
CY2020Q4 mgen Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
29100000 USD
CY2019Q4 mgen Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
46200000 USD
CY2020 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13100000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0 USD

Files In Submission

Name View Source Status
0001590750-21-000029-index-headers.html Edgar Link pending
0001590750-21-000029-index.html Edgar Link pending
0001590750-21-000029.txt Edgar Link pending
0001590750-21-000029-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fy202010kex1014.htm Edgar Link pending
fy202010kex1017.htm Edgar Link pending
fy202010kex1018.htm Edgar Link pending
fy202010kex102.htm Edgar Link pending
fy202010kex1023.htm Edgar Link pending
fy202010kex103.htm Edgar Link pending
fy202010kex211.htm Edgar Link pending
fy202010kex231.htm Edgar Link pending
fy202010kex311.htm Edgar Link pending
fy202010kex312.htm Edgar Link pending
fy202010kex321.htm Edgar Link pending
fy202010kex45.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mgen-20201231.htm Edgar Link pending
mgen-20201231.xsd Edgar Link pending
mgen-20201231_cal.xml Edgar Link unprocessable
mgen-20201231_def.xml Edgar Link unprocessable
mgen-20201231_g1.jpg Edgar Link pending
mgen-20201231_g2.jpg Edgar Link pending
mgen-20201231_g3.jpg Edgar Link pending
mgen-20201231_g4.jpg Edgar Link pending
mgen-20201231_htm.xml Edgar Link completed
mgen-20201231_lab.xml Edgar Link unprocessable
mgen-20201231_pre.xml Edgar Link unprocessable
mgen1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending